Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1GATA2 Deficiency 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Specimen Handling 71Magnetic Resonance Spectroscopy 55Biopsy 43pembrolizumab 25Carboplatin 25Radiation 24Radiotherapy 23Cyclophosphamide 23Nivolumab 21Paclitaxel 20Cisplatin 20olaparib 18Etoposide 18Doxorubicin 17X-Rays 16Vincristine 16Taxes 15Immunoglobulin G 15Disulfides 15Radiotherapy, Intensity-Modulated 14Leucovorin 14Dexamethasone 14Cytarabine 14Bevacizumab 14durvalumab 13Prednisone 13Platinum 131,2-diaminocyclohexaneplatinum II citrate 13Methotrexate 11Ipilimumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Vorinostat × 30 days × Clear all
NCT01522976 2026-05-29

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡